Samuel Svensson
Chief Executive Officer NEOGAP Therapeutics AB
Samuel brings over 25 years of experience in pharmaceutical development to Neogap. He has served as Head of Department and Project Leader at AstraZeneca R&D, where he successfully took three substances from development into phase I clinical trials. Samuel is also a Co-founder of Alzecure Foundation and serves as a Board Member for Biopercept Ltd, Celluminova, and Oxiant Discovery.
In addition to his industry experience, Samuel is an Adjunct Professor of Pharmacology and Chemistry at Linköping University, where he contributes to the education and training of the next generation of scientists.
Seminars
Thursday 19th November 2026
Q&A & Panel Discussion: Evaluating TIL Programs Through an Investor Lens to Drive Sustainable Growth
2:15 pm
- Examining how TIL leaders are balancing clinical efficacy, manufacturing complexity, and capital efficiency as investors become increasingly selective following capital-intensive cell therapy experiences
- Discussing the strategic decisions CEOs face when prioritizing indications, advancing next-generation platforms, pursuing partnerships, and managing development risk in a constrained funding environment
- Identifying the clinical, operational, and commercial milestones that most effectively rebuild investor confidence, support sustainable financing, and create long-term enterprise value
